Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Now approved for both acute and chronic HCV in adults and children aged 3 and above
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
The company received 1 (One) observation in the Form-483
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Subscribe To Our Newsletter & Stay Updated